URGN UroGen Pharma Ltd.
Price Chart
Executive Summary
UroGen Pharma settled patent litigation with Teva over Jelmyto (mitomycin) for pyelocalyceal solution. Under the settlement, UroGen grants Teva a non-exclusive license to sell a generic version beginning September 15, 2030, if FDA-approved. The agreement resolves all ongoing patent litigation in the U.S. District Court for the District of Delaware and is subject to FTC/DOJ review.
Actionable Insight
The settlement removes patent litigation overhang and provides clarity on generic entry timing (Sept 2030). Monitor FTC/DOJ review outcome and any potential impact on Jelmyto revenue trajectory. The 4+ year runway to generic entry is a modest positive for Jelmyto's commercial outlook.
Key Facts
- UroGen entered a settlement and license agreement with Teva resolving patent litigation over Jelmyto (mitomycin) for pyelocalyceal solution.
- Teva will receive a non-exclusive license to sell its generic version of Jelmyto beginning September 15, 2030, if FDA-approved.
- All ongoing patent litigation between the parties in the U.S. District Court for the District of Delaware will be terminated.
- The agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
- No financial terms of the settlement were disclosed in the filing.
Financial Impact
No financial terms disclosed. The settlement removes litigation uncertainty and establishes a generic entry date of September 15, 2030, which is approximately 4+ years from now.
Risk Factors
- FTC or DOJ could challenge or modify the settlement terms.
- Earlier generic entry if certain limited customary circumstances occur.
- No financial terms disclosed — potential undisclosed royalty or payment structure could alter the economic impact.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-019102 |
| Document: 0001437749-26-019102-index-headers.html | 0001437749-26-019102 |
| Document: 0001437749-26-019102-index.html | 0001437749-26-019102 |
| Document: 0001437749-26-019102.txt | 0001437749-26-019102 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
10d ago
|
8-K
| $26.54 $26.60 | ▲ +0.23% | ▲ +0.92% | $29.72 (+11.98%) |
|
May 16, 2026
27d ago
|
ANALYST-UPGRADE
| $14.34 $13.24 | ▼ −7.67% | ▼ −6.83% | $29.72 (+107.25%) |
|
May 6, 2026
5w ago
|
Press Release
| $26.25 $26.59 | ▲ +1.30% | ▲ +1.63% | $29.72 (+13.22%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $23.34 $23.83 | ▼ −2.10% | ▼ −1.08% | $29.72 (−27.34%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $21.39 $22.54 | ▲ +5.38% | ▲ +4.16% | $29.72 (+38.94%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $19.02 $18.82 | ▼ −1.05% | ▼ −0.14% | $29.72 (+56.26%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $19.02 $18.82 | ▼ −1.05% | ▼ −0.14% | $29.72 (+56.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access